
PAVmed Investor Relations Material
Latest events

Q2 2025
PAVmed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PAVmed Inc
Access all reports
PAVmed Inc. holds interests in various medical device technologies at various stages of development. Its initial pipeline includes: carPIX, a technology that transforms the humble stethoscope into a highly effective imaging tool; EsoGuard/EsoCheck, a novel, multi-marker screening test for esophageal cancer and Barrett's esophagus; PortIO, an implantable intraosseous vascular access device that could revolutionize the way patients needing vascular access are treated.
NextCath, a revolutionary self-anchoring catheter technology based on an internally developed platform that eliminates the need for sutures or tissue adhesives to secure a catheter to the body; and NextVessel, which is being developed by NextCath Inc., and is designed to provide early detection of coronary atherosclerosis and other vascular conditions. PAVmed Inc. was founded in 2014 and is headquartered in New York, New York.
Key slides for PAVmed Inc


Q1 2025
PAVmed Inc


Q2 2025
PAVmed Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
PAVM
Country
🇺🇸 United States